DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream

Information source: Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Atopic Dermatitis

Intervention: Locoid Lipocream (Drug); Hylatopic Plus (Drug)

Phase: N/A

Status: Completed

Sponsored by: Icahn School of Medicine at Mount Sinai

Official(s) and/or principal investigator(s):
Joshua Zeichner, MD, Principal Investigator, Affiliation: Icahn School of Medicine at Mount Sinai


The purpose of this study is to evaluate the safety and tolerability, as well as effectiveness, with regards to the order of application for Locoid Lipocream and Hylatopic Plus cream in patients with atopic dermatitis (AD), which is a type of skin rash. Topical skin barrier repair therapies (BRT) that are plain moisturizing creams/lotions with added lipids (fats/oils), such as Hylatopic Plus cream, have emerged as an effective addition to the the treatment of atopic dermatitis. BRTs are often used along with topical steroids (medicated creams), such as Locoid lotion, on skin with AD, and as a monotherapy (single treatment) on both non-diseased and diseased skin. Since BRTs help to restore components of skin that are absent in skin with AD, it is believed that long-term BRT use may reduce further development of further AD. This is an open-label, single site study.

Clinical Details

Official title: Assessment of Application Order When Utilizing Locoid Lotion and Hylatopic Plus Cream in the Treatment of Atopic Dermatitis

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Change from Baseline Treatment Success at Day 29

Secondary outcome:

Change from Baseline SPGA scale at Day 29

Change from Baseline Pruritus at Day 29


Minimum age: 3 Months. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- subjects of at least 3 months of age.

- clinical diagnosis of stable mild to moderate AD using the Hanifin and Rajka criteria

for diagnosing AD

- AD lesions of similar size and severity of bilateral anatomic location

- a SPGA score of 2 or 3 and at least 10% BSA involvement at baseline

- in good health, without evidence of disease process(es) that would present patient

safety concerns or confounding factors for assessment of study objectives

- able and willing to understand and sign an informed consent (or if applicable parent

or legal guardian sign an informed consent),

- able and willing to agree to requirements and restrictions of the study

- Subjects who are willing to discontinue all systemic corticosteroids,

immunomodulators, ultra violet light therapy or other medication (investigational or otherwise) that may have an effect on atopic dermatitis disease progression for 30 days prior to the baseline measurement.

- Subjects on a stable maintenance therapy (at least 30 days of use prior to baseline)

of antihistamines and/or nasal spray containing corticosteroids for the treatment of bronchial asthma or allergic rhinitis, and antibiotics for the treatment of acne will be allowed.

- Subjects who are willing to discontinue use of topical treatments for AD including,

but not limited to, corticosteroids, immunomodulators, vitamin D treatments, retinoids, topical antihistamines for at least 14 days prior to baseline

- Subjects who are willing to discontinue use of oral antibiotic therapy for at least 7

days prior to baseline, unless prescribed for acne treatment as previously described

- Subjects with no known allergy to any of the study product ingredients

- Women of childbearing potential must be willing to use a form of birth control during

the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant, Depo-Provera, double barrier methods (e. g., condom and spermicide) and abstinence. Exclusion Criteria:

- immunocompromised patients, or subjects with extensive disease that could not

reasonably be controlled with topical therapy

- history or evidence of other conditions that would interfere with the evaluation of

the study medication

- subjects desiring excessive or prolonged exposure to UV light (e. g. sunlight/tanning

beds) during the study

- Use of topical medications for AD or any other medical condition.

- Subjects currently involved in another clinical research study.

- Subjects, who are pregnant, breast feeding or planning a pregnancy.

- Subjects with clinically significant unstable medical or mental disorders.

- Subjects who are unwilling or unable to comply with the requirements of the protocol.

Locations and Contacts

Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States
Additional Information

Starting date: April 2013
Last updated: June 3, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017